Seeking Alpha

St. Jude Medical, Inc. (STJ)

  • May. 1, 2012, 11:49 AM
    New J&J (JNJ) CEO Alex Gorsky is looking to strengthen the company's medical-device unit via takeovers, he tells Bloomberg in an interview. "We remain committed to cardiovascular," Gorsky says, despite sales shrinking 44% since 2006. On the analyst wish list are Edwards Lifesciences (EW) and St. Jude Medical (STJ).
  • May. 1, 2012, 11:10 AM
    The problems related to the wires of St Jude Medical's (STJ +0.5%) Riata implantable defibrillator, which was recalled late last year, have continued over the past 3 months, a new report shows. The silicone coating around the wire lead eroded at an estimated 0.3% rate, although the report's authors say the figure could be higher.
    | Comment!
  • Apr. 23, 2012, 9:56 AM
    Abbott Laboratories (ABT -0.55%) and St Jude Medical (STJ -1.8%) expand a 2008 agreement to jointly promote each others' cardiovascular products in the U.S. and offer a full complement of devices. Abbot will provide heart stents and St Jude systems that correct irregular heartbeats such as pacemakers.
    | Comment!
  • Apr. 18, 2012, 8:25 AM
    Shares of St. Jude Medical (STJ) move up 0.9% in premarket trading after beating the earnings estimates of analysts with its Q1 report. The firm expects Q2 EPS 2012 of $0.86-$0.88 per share and full-year EPS of $3.44-$3.49 with new products in its pipeline set to be launched.
    | Comment!
  • Apr. 18, 2012, 7:44 AM
    St. Jude Medical (STJ): Q1 EPS of $0.86 beats by $0.03. Revenue of $1.4B (+1.4% Y/Y) in-line. (PR)
    | Comment!
  • Apr. 18, 2012, 12:05 AM
    Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT
    | Comment!
  • Apr. 17, 2012, 5:30 PM
    Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT
    | Comment!
  • Apr. 17, 2012, 1:21 PM
    Canaccord is recommending buying St. Jude Medical (STJ +2%) ahead of its upcoming Q1 report. The firm sees an in-line quarter but feels 2012 guidance is too conservative, saying that with signs of CRM stabilization and new product pipelines, the stocks recent weakness presents a decent buying opportunity for longer-term investors.
    | Comment!
  • Apr. 9, 2012, 2:33 PM
    St. Jude Medical (STJ -4.8%) shares sink after calling attention to a medical journal article that shows Medtronic's (MDT -0.9%) heart device leads resulted in fewer deaths than its recalled Riata and Riata ST products. STJ says the article "substantially undercounted" deaths associated with MDT's Quattro Secure device and wants it retracted.
    | Comment!
  • Apr. 4, 2012, 10:24 AM
    St. Jude Medical (STJ -5.3%) will stop selling its QuickSite and QuickFlex left-ventricular leads, wires that help pace the heart in patients with heart failure, after 39 reports of the wires protruding from their insulation. STJ has been dealing with the same problem in its recalled Riata wires that connect life-saving defibrillators to the heart.
    | Comment!
  • Apr. 2, 2012, 12:21 PM
    Lazard Capital downgrades a number of names in the in the Medical Technology space today due to valuation. Intuitive Surgical (ISRG +0.2%), Endologix (ELGX -5.4%), Allergan (AGN -0.4%), St. Jude Medical (STJ -0.7%) and ZOLL Medical (ZOLL +0.1%) are all cut to Neutral.
    | 1 Comment
  • Mar. 27, 2012, 10:21 AM
    Researchers say St. Jude Medical's (STJ +2.1%) recalled Riata wires, used to connect life-saving defibrillators to the heart, can short circuit, a defect that may have led to 22 deaths. Riata and Riata ST wires “are prone to high-voltage failures that have resulted in death,” according to a study to be published.
    | Comment!
  • Mar. 19, 2012, 2:13 PM
    Kensey Nash (KNSY +24%) jumps after saying it's reached a settlement with St. Jude Medical (STJ -0.6%), resolving its dispute regarding vascular closure device licenses and related claims. Under the deal, St. Jude will pay Kensey $39 million over several quarters.
    | Comment!
  • Mar. 6, 2012, 12:51 PM
    St. Jude Medical (STJ -3.2%) reports a $56M charge for losses in Greece when it failed to receive payments from a distributor. While STJ says revenue from Greece does not impact its 2012 guidance, Citigroup's Matthew Dodds says the "exceedingly large" size of the write-off "makes it pretty clear this was their primary channel" in the country. (also)
    | Comment!
  • Feb. 17, 2012, 10:26 AM
    Edwards Lifesciences (EW) is taking unusual caution in introducing its Sapien heart valve to help ensure good results, a departure from the typical industry strategy of flooding the market to take advantage of a head start. But the strategy is risky, as rivals nip at its heels; a MDT device is available in Europe, and BSX and STJ could have products ready soon.
    | Comment!
  • Feb. 6, 2012, 2:20 PM
    St. Jude Medical (STJ +1%) outperforms after UBS reiterates a Buy following the company's Feb. 3 investor meeting. The firm touts the strength of St. Jude's product pipeline, and expects recent weakness in ICD product sales to be offset by strength in other areas. It also doesn't see "any evidence of a problematic defect" in St. Jude's Durata defilibration lead, in spite of concerns to the contrary.
    | Comment!
Visit Seeking Alpha's
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.